Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegafur + temozolomide + thalidomide
- Development stage
- Unknown
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tegafur + temozolomide + thalidomide is an investigational combination chemotherapy and anti-angiogenic regimen evaluated for the treatment of advanced neuroendocrine tumors (NETs). The regimen, often referred to as the STEM regimen, incorporates S-1 (a combination of the 5-fluorouracil prodrug tegafur with gimeracil and oteracil), the oral alkylating agent temozolomide, and the immunomodulatory drug thalidomide. It was primarily studied in the Phase II STEM trial conducted by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The combination aims to improve outcomes in patients with pancreatic and non-pancreatic NETs by combining cytotoxic DNA damage and antimetabolite activity with the suppression of tumor angiogenesis and cell proliferation.
- Other names
- S-1 + temozolomide + thalidomideSTEM regimen
02
Targets
DNACRBN (Cereblon)TS (Thymidylate synthase)
Beyond the preview
Go deeper on tegafur + temozolomide + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegafur + temozolomide + thalidomide.